Haite Biotechnology: SDIC Securities Co., Ltd.’s Continuous Supervision and Sponsorship Summary Report on the Company’s 2022 Issuance of Stocks to Specific Targets through Simple Procedures
SDIC Securities Co., Ltd.
About Wuhan Haite Biopharmaceutical Co., Ltd.
2022 Continuous Supervision and Sponsorship Summary Report on the Issuance of Stocks to Specific Targets through Simple Procedures
SDIC Securities Co., Ltd. (formerly Essence Securities Co., Ltd., hereinafter referred to as "SDIC Securities" and the "Sponsor") serves as the sponsor for Wuhan Haite Biopharmaceutical Co., Ltd. (hereinafter referred to as "Haite Bio" or the "Company" or the "Issuer") to issue stocks to specific objects through a simplified procedure in 2022, and will perform continuing supervision responsibilities until December 31, 2025. At present, the period of continuous supervision has expired. In accordance with the provisions of the "Measures for the Administration of the Sponsorship Business of Securities Issuance and Listing", "Shenzhen Stock Exchange GEM Stock Listing Rules", "Shenzhen Stock Exchange Self-Regulatory Guidelines for Listed Companies No. 2 - Standardized Operation of GEM Listed Companies" and other relevant regulations and normative documents, the sponsor issued this sponsorship summary report.
1. Commitments of sponsor institutions and sponsor representatives
There are no false records, misleading statements or major omissions in the recommendation summary report, supporting documents and related materials. The sponsor institution and the sponsor representative bear legal responsibility for their authenticity, accuracy and completeness.
Sponsor institutions and sponsor representatives voluntarily accept any inquiries and investigations conducted by the China Securities Regulatory Commission on matters related to the sponsorship summary report.
Sponsor institutions and sponsor representatives voluntarily accept the regulatory measures taken by the China Securities Regulatory Commission in accordance with the relevant provisions of the "Measures for the Administration of the Sponsorship Business of Securities Issuance and Listing".
2. Basic information of sponsor institutions
Sponsor name SDIC Securities Co., Ltd.
Registered address: Anxin Financial Building, No. 119, Fuhua 1st Road, Futian Street, Futian District, Shenzhen
Main office address: Floor 37, No. 168, Yangshupu Road, Hongkou District, Shanghai
Legal representative Wang Suwang
Sponsor representatives Sun Sushu, Yan Yun
Contact person Sun Sushu
Contact number 021-55518389
3. Basic situation of the company
Company Name Wuhan Haite Biopharmaceutical Co., Ltd.
Securities code 300683
Registered address: Haite Science and Technology Park, Wuhan Economic and Technological Development Zone
Main office address: Haite Science and Technology Park, Wuhan Economic and Technological Development Zone
Legal representative Chen Ya
Actual controller Chen Ya
Secretary of the Board of Directors Yang Kun
Contact Yang Kun
Contact number 027-84599931
The type of securities issuance this time is the issuance of stocks to specific objects.
The issuance time of this securities is October 24, 2022
The listing time of this securities is February 15, 2023
The place where the securities are listed is Shenzhen Stock Exchange
4. Overview of recommendation work
- Due diligence recommendation stage
During the due diligence recommendation stage, the sponsor actively coordinates various intermediaries to participate in the issuance and listing of Haite Bio-Securities, conducts due diligence and prudential verification of the company in strict accordance with laws, administrative regulations and the provisions of the China Securities Regulatory Commission, organizes the preparation of application documents and issues recommendation documents; in accordance with the China Securities Regulatory Commission, Shenzhen Securities Regulatory Commission, According to the requirements of the stock exchange, conduct due diligence or verification on specific matters related to the issuance and listing of this securities, and conduct professional communication with the China Securities Regulatory Commission and the Shenzhen Stock Exchange; in accordance with the requirements of the listing rules of the stock exchange, submit relevant documents required for recommending stocks to the stock exchange to the stock exchange and report them to the China Securities Regulatory Commission for filing.
- Continuous supervision stage
During the continuous supervision stage, the main tasks of the sponsor include but are not limited to:
(1) Supervise the issuer and its directors, supervisors, and senior managers to comply with legal provisions, effectively implement and improve the system to prevent controlling shareholders, actual controllers, and other related parties from illegally occupying the issuer's resources, and supervise the issuer to establish, improve, and effectively implement the corporate governance system, including but not limited to the rules of procedure of the general meeting of shareholders or shareholders, the board of directors, and the board of supervisors, and the behavioral norms of directors and senior managers;
(2) Supervise the issuer to effectively implement and improve the internal control system to prevent its directors, supervisors, and senior managers from taking advantage of their positions to harm the issuer's interests, including but not limited to financial management systems, accounting systems, and internal audit systems, as well as procedures and rules for major business decisions such as the use of raised funds, related transactions, external guarantees, external investments, and control of subsidiaries;
(3) Supervise the issuer to effectively implement and improve the system to ensure the fairness and compliance of related-party transactions, and express opinions on related-party transactions;
(4) Supervise issuers to establish, improve and effectively implement information disclosure systems, and review information disclosure documents and other relevant documents;
(5) Continue to pay attention to the fulfillment of commitments made by the issuer and its major shareholders, directors, supervisors, senior managers, etc., and continue to pay attention to commitments such as the special account storage of funds raised by the issuer and the implementation of investment projects;
(6) Continue to pay attention to the situation where the issuer or its controlling shareholders, actual controllers, directors, supervisors, and senior managers are subject to administrative penalties from the China Securities Regulatory Commission, disciplinary sanctions from the stock exchanges, or are issued regulatory attention letters by the stock exchanges;
(7) Continue to pay attention to public media reports about the issuer, and promptly check market rumors; (8) Continue to pay attention to matters such as the issuer's provision of guarantees for others, and express opinions;
(9) Conduct on-site inspections of issuers in accordance with regulatory regulations;
(10) Other tasks stipulated in the provisions of the China Securities Regulatory Commission and stock exchanges and the "Sponsorship Agreement" and "Continuous Supervision Agreement".
5. Major events that occurred during the performance of sponsorship duties and their handling
- Regarding the postponement of some investment projects with raised funds
Although the company's investment projects have undergone sufficient feasibility studies in the early stage, the company's wholly-owned subsidiary Hanrui Pharmaceutical (Jingmen) Co., Ltd. (hereinafter referred to as "Jingmen Hanrui") has completed the construction of two commercial production workshops and supporting projects. It is mainly engaged in the production and sales of antiviral APIs and intermediates. The project investment is large, the depreciation of fixed assets has increased, and the competition in the API industry has reduced revenue, resulting in Jingmen Hanrui suffering serious losses. In order to ensure the stable development of Jingmen Hanrui and reduce the risk of using raised funds, the company has extended the date for the "high-end API R&D pilot project" to reach the expected usable state from February 15, 2025 to February 15, 2026. The company held the 17th meeting of the 8th board of directors and the 17th meeting of the 8th board of supervisors on August 26, 2024, and reviewed and approved the "Proposal on the Extension of Investment Projects with Partial Raised Funds". The company's independent directors issued unanimous independent opinions on the matter.
The sponsor has issued verification opinions on the above matters.
- Regarding changes to some investment projects with raised funds
The company issued shares to specific targets through a simple procedure in 2022, and the funds raised were mainly used to build a "high-end API research and development pilot project." At that time, the scale of the API market continued to grow, domestic API companies saw opportunities, and demand was strong. The company's antiviral workshop for APIs that had been put into production was saturated with orders, and revenue was in line with the company's expectations. However, in the past two years, the two production workshops that Jingmen Hanrui has commercialized have been insufficient in orders and the depreciation of fixed assets has increased, causing Jingmen Hanrui to suffer serious losses. At present, competition in the API industry has intensified, resulting in reduced revenue. Changes in the market environment have led to major changes in supply and demand in the industry. The new production capacity cannot be absorbed. In addition, Jingmen Hanrui is currently suffering from serious losses. In order to ensure the stable development of Jingmen Hanrui and reduce the use risk of raised funds, the raised funds investment project "High-end API R&D Pilot Project" was changed to the "National Class I New Drug Eprenamin New Indications Research Project", and the implementation entity was changed from "Hanrui Pharmaceutical (Jingmen) Co., Ltd." to "Wuhan Haite Biopharmaceutical Co., Ltd." The company held the sixth meeting of the ninth board of directors on December 29, 2025, and reviewed and approved the "Proposal on Changing the Use of Part of the Raised Funds and Closing Some Raised Investment Projects and Using the Surplus Raised Funds to Permanently Supplement Working Capital." The company's independent directors issued unanimous independent opinions on the matter.
The sponsor has issued verification opinions on the above matters.
6. Explanation and evaluation of listed companies’ cooperation with sponsors
- Due diligence recommendation stage
During the due diligence recommendation stage, the issuer can promptly provide the sponsors and other intermediaries with the documents, materials and relevant information required for this securities issuance and listing, and ensure the authenticity, accuracy and completeness of the documents, materials and information provided; in accordance with the requirements of relevant laws and regulations, the issuer actively cooperates with the sponsors and other intermediaries in their due diligence and verification work, providing convenient conditions for the sponsors to carry out the recommendation work for this securities issuance and listing.
- Continuous supervision stage
During the continuous supervision stage, the issuer can standardize operations and perform information disclosure obligations in accordance with the requirements of relevant laws and regulations; for important matters or information disclosure matters, the issuer can communicate with the sponsor in a timely manner and provide relevant documents and materials according to the sponsor's requirements, which provides convenience for the sponsor to perform continuous supervision responsibilities.
7. Explanation and evaluation of securities service institutions’ participation in the issuance and listing of securities
During the due diligence recommendation and continuous supervision stage of this securities issuance and listing, the securities service agency hired by the issuer can promptly issue relevant professional reports, provide professional opinions and suggestions in accordance with the requirements of relevant laws and regulations, and actively cooperate with the sponsor's coordination, verification work and continuous supervision of related work.
8. Concluding opinions on the review of information disclosure of listed companies
In accordance with the relevant regulations of the China Securities Regulatory Commission and stock exchanges, the sponsoring institution conducted a pre-review and post-prompt review of the information disclosure documents related to the sponsorship work during the issuer's continuous supervision period, and supervised the company to strictly fulfill its information disclosure obligations. The sponsor believes that during the continuous supervision period, the issuer will disclose information in accordance with the relevant regulations of the securities regulatory authorities, publicly release various regular reports or temporary reports in accordance with the law, ensure that the disclosure of various major information is true, accurate and complete, and no false records, misleading statements or major omissions are found.
9. Concluding opinions on the review of the use of raised funds by listed companies
The sponsor reviewed the deposit, management and use of funds raised by the issuer and believed that the deposit, management and use of funds raised by the issuer in this securities issuance complied with the relevant regulations of the China Securities Regulatory Commission and the stock exchange. The company has stored and used the raised funds in a special account, and the approval procedures for the use of raised funds are legal and compliant. No disguised changes in the use of raised funds and harm to the interests of shareholders have been found, and no major violations of the use of raised funds have been found.
10. Other matters required by the China Securities Regulatory Commission and stock exchanges
None.
(No text below)
(This page has no text, but is the signature and seal page of the "SDIC Securities Co., Ltd.'s Continuous Supervision and Sponsorship Summary Report on Wuhan Haite Biopharmaceutical Co., Ltd.'s Continuous Supervision and Sponsorship Summary Report on the Issuance of Stocks to Specific Targets under Simple Procedures in 2022")
Sponsor representative:
Sun Sushu Yan Yun
SDIC Securities Co., Ltd.
May 6, 2026 (This page has no text, but is the signature and seal page of "SDIC Securities Co., Ltd.'s Continuous Supervision and Sponsorship Summary Report on Wuhan Haite Biopharmaceutical Co., Ltd.'s Issuance of Stocks to Specific Targets under Simple Procedures in 2022")
Legal representative:
Wang Suwang
SDIC Securities Co., Ltd.
May 6, 2026